AstraZeneca-AZN Q3 Earnings Top Estimates, Sales Rise As Most Key Drugs Outperform

Key Takeaways AZN's Q3 core EPS of $1.19 beat estimates, rising 14% as revenues climbed 12% to$ 15.19 billionTagrisso, Imfinzi, Farxiga, Symbicort and Fasenra all topped sales forecasts, driving double-digit growth.AZN reaffirmed 2025 guidance, expecting high single-digit revenue growth and a low double-digit EPS rise.AstraZeneca’s (AZN) third-quarter 2025 core earnings of $1.19 per American depositary share (ADS) beat the Zacks Consensus Estimate of$ 1.14 per share. Core earnings of $2.38 per share rose 14 ...